Search
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationaloccurs in a pH-dependent manner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the … Enspryng®, a satralizumab formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors
Categories: Interleukin-6 Receptor AntagonistSynonyms: Humanised anti-IL-6 receptor monoclonal antibodyBromotheophylline
go.drugbank.com/drugs/DB14018ApprovedBromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. … From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingSynonyms: 8-BromotheophyllineAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … including biologics, or when the use of those therapies is inadvisable.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsProducts: CIBINQO® 100MG, CIBINQO® 50 MGOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.
Mixtures: ZEPOSIA 7-Day Starter Pack, ZEPOSIA 7-Day Starter PackCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesFloxuridine
go.drugbank.com/drugs/DB00322ApprovedInvestigationalAn antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. … When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Heterocyclic Compounds, 1-RingSynonyms: 1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil, 1-beta-D-2'-Deoxyribofuranosyl-5-flurouracilHydroxycitronellal
go.drugbank.com/drugs/DB14187ApprovedHydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain … Sensitivity to hydroxycitronellal may be identified with a clinical patch test.
Synonyms: 3,7-dimethyl-7-hydroxyoctan-1-al, 7-hydroxycitronellalForeskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedThe barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes. … A gel made of bovine collagen is used as the matrix for cell growth and differentiation.
Aluminum oxide
go.drugbank.com/drugs/DB11342ApprovedWithdrawnIt is considered an indirect additive used in food contact substances by the FDA. … Aluminum oxide has a chemical formula Al2O3. It is amphoteric in nature, and is used in various chemical, industrial and commercial applications.
Mixtures: POLGENTEC 2-120 GBQ GENERADOR DE RADIONUCLEIDOSProducts: ALUMINIUM HYDROXIDE MIXTURE BP 4% w/w, ALUTACID ANTACID MIXTURE 4% w/wFluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalThough it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein inhibitorsProducts: VERLIN TABLETAS X 50 MG, VOXAMIN® TABLETA RECUBIERTAEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide. … Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MG